Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Stefan Schreiber, Shomron Ben‐Horin, Rieke Alten, et al.
Advances in Therapy (2022) Vol. 39, Iss. 6, pp. 2342-2364
Open Access | Times Cited: 22

Showing 22 citing articles:

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)
Stephen B. Hanauer, Bruce E. Sands, Stefan Schreiber, et al.
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 919-933
Open Access | Times Cited: 10
The role of immunogenicity in optimizing biological therapies for inflammatory bowel disease
Konika Sharma, Brad W. deSilva, Stephen B. Hanauer
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics
Robert D. Little, Mark G. Ward, Emily K. Wright, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 20, pp. 6173-6173
Open Access | Times Cited: 23
A new perspective on gut-lung axis affected through resident microbiome and their implications on immune response in respiratory diseases
Cong Xu, Mengqi Hao, Xiaohu Zai, et al.
Archives of Microbiology (2024) Vol. 206, Iss. 3
Closed Access | Times Cited: 4
Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial
Stefan Schreiber, Geert R. D’Haens, Fraser Cummings, et al.
Digestive and Liver Disease (2024) Vol. 56, Iss. 7, pp. 1204-1212
Open Access | Times Cited: 3
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Julia Husman, Karin Černá, Katja Matthes, et al.
International Journal of Colorectal Disease (2024) Vol. 39, Iss. 1
Open Access | Times Cited: 3
Neutrophil diversity and function in health and disease
F Zhang, Yidan Xia, Jiayang Su, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 3
Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit
Rieke Alten, Yoorim An, Dong‐Hyeon Kim, et al.
Clinical Drug Investigation (2022) Vol. 42, Iss. 6, pp. 477-489
Closed Access | Times Cited: 17
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Laurent Peyrin‐Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Subcutaneous Infliximab in Refractory Crohn’s Disease Patients: A Possible Biobetter?
Karin Cerna, Dana Ďuricová, Martin Lukás, et al.
Crohn s & Colitis 360 (2023) Vol. 5, Iss. 4
Open Access | Times Cited: 7
Proinflammatory cytokines and their receptors as druggable targets to alleviate pathological pain
Theodora Kalpachidou, Lydia Riehl, Clemens L. Schöpf, et al.
Pain (2022) Vol. 163, Iss. S1, pp. S79-S98
Closed Access | Times Cited: 11
Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview
Yeo‐Jin Song, Seoung Wan Nam, Chang‐Hee Suh, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 11, pp. 751-768
Closed Access | Times Cited: 6
Customer-centric product presentations for monoclonal antibodies
Beate Bittner
AAPS Open (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 5
Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review
Massimo Claudio Fantini, Erica Loddo, Amalia Di Petrillo, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 1, pp. 1-6
Open Access | Times Cited: 4
Anti-SARS-CoV-2 Biotherapeutics and Chemotherapeutics: An Insight into Product Specifications and Marketing Dynamics
Vijay Kotra, Dinakar Mallem, Anil Kumar Kanuri, et al.
Progress In Microbes & Molecular Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 7
Designing for medication adherence in inflammatory bowel disease: multi-disciplinary approaches for self-administrable biotherapeutics
Vivian R. Feig, Sufeng Zhang, Ashka Patel, et al.
EClinicalMedicine (2024) Vol. 77, pp. 102850-102850
Open Access
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Bo‐In Lee, Minjee Kim, Eun Ran Kim, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis
Xinyue Hu, Xiaowei Tang, Limin Li, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access
A Comparison of Intravenous Infliximab versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Alejandro Nieto Dominguez, Abhishek Bhurwal, Hemant Mutneja, et al.
Gastro Hep Advances (2024) Vol. 4, Iss. 3, pp. 100588-100588
Open Access
Subcutaneous versus intravenous infliximab therapy – a real-world study: toward higher drug concentrations
Ana Isabel Ferreira, Tiago Lima Capela, Cátia Arieira, et al.
European Journal of Gastroenterology & Hepatology (2024) Vol. 36, Iss. 11, pp. 1314-1318
Closed Access
The Impact of the COVID-19 Pandemic on Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey
Laurent Peyrin‐Biroulet, Anna Karoliina Ylanne, Allyson Sipes, et al.
Advances in Therapy (2023) Vol. 41, Iss. 2, pp. 598-617
Open Access | Times Cited: 1
Opciones terapéuticas disponibles ante la falla al tratamiento anti-TNF en pacientes con Enfermedad Inflamatoria Intestinal
Ignacio Alfaro, Carolina Figueroa, Carolina Pavez Ovalle, et al.
Revista Gastroenterología Latinoamericana (2023) Vol. 34, Iss. 2
Open Access
Page 1

Scroll to top